Thatcher, Nick <br/><br/>
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  Jul 2015 
 - 763-74 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(15)00021-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Gentamicins--administration & dosage<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Proportional Hazards Models<br/>Risk Assessment<br/>Sex Factors<br/>Survival Analysis<br/>Treatment Outcome